SAN FRANCISCO—The ability of cancer cells to evolve clonally into molecularly distinct strands needs to be considered when selecting targeted therapies to treat renal cancer, according to Dr Tom Powle
SAN FRANCISCO—The ability of cancer cells to evolve clonally into molecularly distinct strands needs to be considered when selecting targeted therapies to treat renal cancer, according to Dr Tom Powles MBBS, MRCP, MD speaking at the ASCO GU Cancers Symposium here. Dr Tomasz Beer, MD FACP from Oregon Health & Science University in Portland acknowledged that heterogeneity was also a barrier to prostate cancer treatment but he felt it would be overcome in this and other genitourinary cancers by using combination targeted therapies just as HIV-AIDS was being beaten by multi-drug approaches.
CONTACT:
Dr. Tom Powles MBBS, MRCP, MD
Barts Cancer Institute, London, UK SOURCE:
SOURCE:
General Session: Clinical and genetic heterogeneity in renal cell carcinoma
LINK: http://gucasym.org/2014-meeting-program#Saturday
Related Episodes
Which High-Risk Prostate Cancers Need Multimodality Treatment?
MILAN, Italy—Patients with node-positive prostate cancer being treated with prostatectomy could derive benefit from early multimodality therapy combining androgen deprivation therapy (ADT) with radiot
Gene Assay Predicts Which Patients Need Radiation After Prostatectomy
ARTICLE MILAN, Italy—Genomic testing combined with clinical assessment could be the best way to identify patients with prostate cancer who can benefit from early radiotherapy after prostatectomy, acco